Indovac and Inavac vaccines are targeted to get an emergency use permit (EUA) from BPOM in September 2022.
The head of the Indonesian Food and Drug Supervisory Agency (BPOM), Penny K. Lukito, stated that President Joko Widodo (Jokowi) had approved the names of two domestically made COVID-19 vaccine products.
"I am proud for Indonesia. Indovac's first vaccine is for BUMN vaccines, and the second is the Red and White Vaccine with an inactivated virus platform, the name Inavec has been approved by the President," said Penny in the agenda of the Domestic Drug Development Workshop at the Ayana MidPlaza Hotel, Jakarta.
Penny said the Indovac vaccine with a sub-unit recombinant protein platform was developed by the Eijkman Institute for Molecular Biology together with PT Bio Farma and Baylor College of Medicine.
Meanwhile, the Inavac vaccine with an inactivated virus platform was developed by the Research Team from Universitas Airlangga (Unair) in collaboration with production facility provider PT Biotis Pharmaceutical Indonesia.
Penny targets the Indovac and Inavac vaccines to obtain an emergency use permit (EUA) from the Indonesian National Food and Drug Administration (BPOM) in September 2022.
"Phase two has been passed, and the results are good, it can improve the immune system and the results are not inferior to vaccines that have received EUA with the same technology," he said.
Currently, BPOM is still conducting a review of research reports on thousands of subjects who underwent a second injection in each trial laboratory.
The third phase of clinical trials of two domestic vaccines is also accompanied by the granting of permits for clinical trial activities for booster vaccines or booster doses.
"The booster clinical trial has been approved to be carried out by the end of this year. So the booster vaccination program with domestic vaccines can be completed before the end of the year," he said. (antara)
